Medical technology company Medtronic has received approval from the US Food and Drug Administration (FDA) for its two new cardiac resynchronization therapy quadripolar leads.
The new Attain Performa left ventricular (LV) quadripolar leads can be coupled with the Medtronic Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D) and treat heart failure patients.
Medtronic Cardiac Rhythm and Heart Failure Business medical director and Heart Failure vice-president and general manager David Steinhaus said: "With the two new shapes, the Attain Performa quadripolar lead portfolio gives physicians more options than any other CRT-D system available in the United States."
The new S-shape and Straight leads are aimed at accommodating patients’ different vessel sizes and curvatures to improve successful lead placement.
Using Quadripolar leads, physicians will be able to boost cardiac resynchronisation therapy, which involves an implantable device to enhance heart’s pumping efficiency.
However, the company’s three Attain Performa lead shapes including Dual Cant Model 4298, Straight Model 4398 and S-Shape Model 4598 are aimed at catering to a range of anatomies without compromising lead usage or stability.
Compatible with the company’s latest CRT device portfolio, the Viva Quad XT and Viva Quad S CRT-D systems, the three leads provide 16 pacing configurations and smaller spacing between the two centre electrodes.
Vanderbilt Heart and Vascular Institute associate professor George Crossley said: "While optimal lead positioning has been shown to improve CRT response rates, every patient is different, making lead placement and stability a common challenge that can result in nonresponse to therapy.
"Having access to a range of lead shapes that work with one CRT-D system gives physicians the ability to help our heart failure patients, even if their cardiac anatomy is challenging."
The Viva Quad XT CRT-D is integrated with Medtronic-exclusive AdaptivCRT algorithm, which preserves normal heart rhythms and automatically adapts to patient requirements and enhance heart failure patients’ response rate to therapy.
Further, Medtronic’ has also launched the new FDA approved cardiac resynchronization therapy quadripolar leads.